Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT00134680 Completed - Clinical trials for Metastatic Breast Cancer

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Start date: January 2000
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®) has on breast cancer. The United States (US) Food and Drug Administration has approved both letrozole and Herceptin for the treatment of advanced breast cancer. Doctors hope that the combination will work better than either drug alone.

NCT ID: NCT00065325 Completed - Clinical trials for Metastatic Breast Cancer

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

EFECT
Start date: August 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

NCT ID: NCT00051103 Completed - Clinical trials for Metastatic Breast Cancer

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

Start date: October 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.